



2 December 2022

ISSUE OF SHARES UNDER PLACEMENT

Vectus Biosystems Limited (ASX:VBS) (Vectus or the Company) advises that today it has issued 4,566,337 new fully paid ordinary shares to a number of sophisticated investors under the Placement announced on 23 November 2022. The issue was completed at a price of \$0.80 per share, and raised \$3,653,069.60 before costs. The net proceeds of the Placement will be used to accelerate the Phase Ib clinical trial for VB0004, which targets the prevention and reversal of fibrosis in the heart and kidneys. Proceeds will also be used to advance Vectus' other emerging lead compounds and for working capital.

Cleansing Notice Under Section 708A(5)(e)

Vectus advises that on 2 December 2022 the Company issued a total of 4,566,337 new fully paid ordinary shares, as set out above. The Company also advises that:

- (1) this notice is being given within five business days after the day of the issue under section 708A(5)(e) of the Corporations Act 2001 (Cth);
- (2) the Company issued the securities without disclosure to investors under Part 6D.2 of the Corporations Act 2001;
- (3) as at the date of this notice, The Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act 2001 as they apply to the Company; and
 - (b) section 674 of the Corporations Act 2001; and
- (4) except as may be set out in this notice, there is no other information that is excluded information as at the date of this notice that is required to be set out in this notice under section 708A(6)(e) of the Corporations Act 2001.

Vectus Biosystems Limited

Robert J Waring
Company Secretary

This announcement was authorised by the Vectus Disclosure Committee.

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137

3-11 Primrose Avenue, Rosebery, NSW 2018 Telephone: +61 2 9381 1000 Facsimile: +61 2 9662 1720

Website: www.vectusbiosystems.com.au